Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the optimal dose of glargine insulin when
converting from intravenous short-acting continuous insulin infusions in surgical and
intensive care unit patients using a prospective, controlled, parallel group, randomized
study design.
Note: Lantus insulin is the proprietary name for glargine insulin.